Pay in 4 interest-free payments of $7.02 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
not FDA-approved as of January 2025 Best Phase 2 result / 24.2% mean body weight loss at 48 weeks (12 mg dose, N=338 trial) Extended estimate / 28.7% mean weight loss projected at 68 weeks in Phase 2 modeling Dosing schedule / Once weekly subcutaneous injection (doses 1 mg through 12 mg tested) Comparator benchmark / Semaglutide 2.4 mg: 14.9% at 68 weeks (STEP-1, N=1,961) Comparator benchmark / Tirzepatide 15 mg: 20.9% at 72 weeks (SURMOUNT-1, N=2,539) Primary side effects / Nausea, vomiting, diarrhea, constipation (dose-dependent) Phase 3 status / Phase 3 program (TRIUMPH trials) enrolling as of 2024 Manufacturer / Eli Lilly and Company What Is Retatrutide
Semaglutide GLP-1 has shown promising results in clinical trials for weight management
McNally, A., Thomson, N
What Clinical Data Shows Joint pain is not listed as a common side effect in Wegovy's original clinical trials, yet patient reports on social media and in medical forums have raised concerns
US$ 22.91
US$ 26.14
US$ 27.04
US$ 21.43
US$ 23.09
US$ 20.13
